Detalhe da pesquisa
1.
Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding.
Antimicrob Agents Chemother
; 46(9): 2969-76, 2002 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-12183255